

# **Non-Steroidal Antioestrogens**

**Molecular Pharmacology and Antitumour Activity**

**Robert L. Sutherland**

**V. Craig Jordan**

# **Non-Steroidal Antioestrogens**

**Molecular Pharmacology and Antitumour Activity**

Edited by

**Robert L. Sutherland**

*Ludwig Institute for Cancer Research  
University of Sydney*

and

**V. Craig Jordan**

*Ludwig Institute for Cancer Research  
Inselspital, Universitat Bern*

1981



**ACADEMIC PRESS**

*A Subsidiary of Harcourt Brace Jovanovich, Publishers*

Sydney New York London Toronto San Francisco

Copyright © 1981 by  
ACADEMIC PRESS AUSTRALIA

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher.

Printed in Australia

---

*National Library of Australia Cataloguing-in-Publication Data*

Non-steroidal antioestrogens.

Bibliography  
Includes index  
ISBN 0 12 677880 9

I. Breast—Cancer. 2. Cancer—Chemotherapy.

I. Sutherland, Robert L. (Robert Lindsay).

II. Jordan, V. Craig (Virgil Craig).

(Series: Ludwig symposia; no. 1).

616.99'449061

---

*Library of Congress Catalog Card Number:* 81-67869

## Non-Steroidal Antioestrogens



Y074495

## LUDWIG SYMPOSIA

---

1. Non-Steroidal Antioestrogens: Molecular Pharmacology and Antitumour Activity  
R.L. SUTHERLAND and V.C. JORDAN (Eds)
2. Nucleosides and Cancer Treatment: Rational Approaches to Antimetabolite  
Selectivity and Modulation  
M.H.N. TATTERSALL and R.M. FOX (Eds)

This book is dedicated to the memory of Dr A. L. Walpole

## Preface

It is now more than twenty years since the first report of an effective non-steroidal antioestrogen, MER 25, was published. This original work inspired many research groups to synthesize and test related compounds as potential antifertility agents. However, the only compounds to reach the clinic (clomiphene and tamoxifen) proved to be inducers of ovulation and are now used routinely in sub-fertile patients.

The work by Dr Elwood V. Jensen and others, which suggested some human breast cancers were directly dependent on oestrogen, led to the initiation of clinical trials with synthetic antioestrogens. Encouraging preliminary results with nafoxidine were offset by a high incidence of troublesome side-effects. However, the successful introduction of tamoxifen for the treatment of advanced breast cancer has resulted in a renewed interest in the pharmacology and mechanisms of action of these drugs.

The exponential increase in the number of research articles on antioestrogenic mechanisms throughout the 1970s prompted us to attempt to summarize the wealth of available data in a single volume. As a basis, much of the information published in this book was presented at an Antioestrogen Workshop held at the Ludwig Institute for Cancer Research, University of Sydney, Australia between the 4th and 6th February, 1980. Due primarily to limitations of space we have only been able to include those areas of antioestrogen research that relate to the development and action of antioestrogens as anticancer agents. For this reason a substantial literature on the effects of antioestrogens in reproductive and behavioural biology has not been included.

The untimely death of Dr Arthur L. Walpole in 1977 unfortunately did not allow him to witness the world-wide acceptance of tamoxifen as an effective

therapy for advanced breast cancer. Tamoxifen was developed by Drs M. J. K. Harper, D. Richardson and A. L. Walpole as part of the fertility control programme at Imperial Chemical Industries Ltd, Pharmaceutical Division, but it was Dr Walpole's deep interest in cancer research that led to its ultimate introduction as an antitumour agent. On a personal note, Dr Walpole was known as a scientist who helped and encouraged young investigators, including one of the editors of this volume (V.C.J.). It is for these reasons that we have dedicated this volume to his memory.

The keen interest shown by the UICC, Imperial Chemical Industries Ltd, Eli Lilly and Co. and Upjohn Pty Ltd in both the Antioestrogen Workshop and the preparation of this volume is gratefully acknowledged.

Finally we would like to thank Christine Cook, Elaine Heffernan, Leigh Murphy, Anne Whybourne, Terry Foo, Mike Green, Roger Reddell and Colin Watts without whose help this venture would not have been possible.

Rob Sutherland  
Craig Jordan



## List of Contributors

Numbers in parentheses indicate the pages on which the authors' contributions begin.

- H. K. Adam (59), Safety of Medicines Department, ICI Pharmaceuticals Division, Alderley Park, Macclesfield, Cheshire, SK10 4TG, U.K.
- D. J. Adams (339), Department of Medicine/Oncology, University of Texas Health Science Center, San Antonio, Texas 78284, U.S.A.
- S. C. Aitken (365), Medicine Branch, National Cancer Institute, Bethesda, Maryland 20205, U.S.A.
- J. C. Allegra (365), Medicine Branch, National Cancer Institute, Bethesda, Maryland 20205, U.S.A.
- K. E. Allen (31, 261), Department of Pharmacology, The Worsley Medical and Dental Building, The University of Leeds, LS2 9JK, U.K.
- B. Arafah (435), Department of Medicine, Case Western Reserve University, School of Medicine, Cleveland, Ohio 44106, U.S.A.
- E. E. Baulieu (177, 249, 413), Unité de Recherches sur le Métabolisme Moléculaire et la Physio-Pathologie des Stéroïdes, INSERM U 33, Medical School, University of Paris-Sud. Lab Hormones, 94270 Bicêtre, France.
- N. Binart (177), Unité de Recherches sur le Métabolisme Moléculaire et la Physio-Pathologie des Stéroïdes, INSERM U 33, Medical School, University of Paris-Sud. Lab Hormones, 94270 Bicêtre, France.
- J. L. Borgna (85,355), Unité d'Endocrinologie Cellulaire et Moléculaire (INSERM U 148), 60 rue de Navacelles, 34100 Montpellier, France.
- N. M. Borthwick (281), Tenovus Institute for Cancer Research, Welsh National School of Medicine, Heath Park, Cardiff CF4 4XX, U.K.
- F. Capony (85, 215), Department of Pharmacological Sciences, Health Sciences Center, State University of New York at Stony Brook, Stony Brook, New York 11794, U.S.A.
- M. G. Catelli (177), Unité de Recherches sur le Métabolisme Moléculaire et la Physio-Pathologie des Stéroïdes, INSERM U 33, Medical School, University of Paris-Sud. Lab Hormones, 94270 Bicêtre, France.
- E. R. Clark (31), Department of Pharmacology, The Worsley Medical and Dental Building, The University of Leeds, LS2 9JK, U.K.

- J. H. Clark (113), Department of Cell Biology, Baylor College of Medicine, Houston, Texas 77030, U.S.A.
- E. Coezy (355), Unité d'Endocrinologie Cellulaire et Moléculaire (INSERM U 148), 60 rue de Navacelles, 34100 Montpellier, France.
- C. P. Daniel (281), Tenovus Institute for Cancer Research, Welsh National School of Medicine, Heath Park, Cardiff CF4 4XX, U.K.
- P. Davies (281), Tenovus Institute for Cancer Research, Welsh National School of Medicine, Heath Park, Cardiff CF4 4XX, U.K.
- C. J. Dix (261), Department of Pharmacology, The Worsley Medical and Dental Building, The University of Leeds, LS2 9JK, U.K.
- D. P. Edwards (339), Department of Medicine/Oncology, University of Texas Health Science Center, San Antonio, Texas 78284, U.S.A.
- C. W. Emmens (17), Department of Obstetrics and Gynaecology, University of Sydney, N.S.W. 2006, Australia.
- R. W. Evans (165), Worcester Foundation for Experimental Biology, Shrewsbury, Massachusetts 01545, U.S.A.
- E. R. Ferguson (95), Department of Physiology and Biophysics, University of Illinois, and School of Basic Medical Sciences, University of Illinois College of Medicine, Urbana, Illinois 61801, U.S.A.
- M. S. Foo (195, 317), Ludwig Institute for Cancer Research, University of Sydney, N.S.W. 2006, Australia.
- C. Geynet (177), Unité de Recherches sur le Métabolisme Moléculaire et la Physiopathologie des Stéroïdes, INSERM U 33, Medical School, University of Paris-Sud. Lab Hormones, 94270 Bicêtre, France.
- S. R. Glasser (113), Department of Cell Biology, Baylor College of Medicine, Houston, Texas 77030, U.S.A.
- M. D. Green (317, 397), Ludwig Institute for Cancer Research, University of Sydney, N.S.W. 2006, Australia.
- R. Hähnel (177), University of Western Australia, King Edward Memorial Hospital, Subiaco, W.A. 6008, Australia.
- J. R. Hayes (95), Department of Physiology and Biophysics, University of Illinois, and School of Basic Medical Sciences, University of Illinois College of Medicine, Urbana, Illinois 61801, U.S.A.
- W. H. Hendry III (165), Worcester Foundation for Experimental Biology, Shrewsbury, Massachusetts 01545, U.S.A.
- V. C. Jordan (31, 261, 473), Department of Human Oncology, Wisconsin Clinical Cancer Center, 600 Highland Avenue, University of Wisconsin, Madison, Wisconsin 53792, U.S.A.
- B. S. Katzenellenbogen (95, 303), Department of Physiology and Biophysics, University of Illinois, and School of Basic Medical Sciences, University of Illinois College of Medicine, Urbana, Illinois 61801, U.S.A.
- J. A. Katzenellenbogen (95), Department of Chemistry, University of Illinois, and School of Basic Medical Sciences, University of Illinois College of Medicine, Urbana, Illinois 61801, U.S.A.
- J. L. Keene (231), Department of Physiology, St. Louis University Medical Center, St. Louis, Missouri 63104, U.S.A.

- Z. S. Krozowski (317), Department of Biochemistry, Royal Prince Alfred Hospital, Camperdown, N.S.W. 2050, Australia.
- N. C. Lan (95), Department of Physiology and Biophysics, University of Illinois, and School of Basic Medical Sciences, University of Illinois College of Medicine, Urbana, Illinois 61801, U.S.A.
- C. B. Lazier (215), Department of Biochemistry, Dalhousie University, Halifax, Nova Scotia, B3H 4H7, Canada.
- W. W. Leavitt (165), Worcester Foundation for Experimental Biology, Shrewsbury, Massachusetts 01545, U.S.A.
- M. C. Lebeau (249), Unité de Recherches sur le Métabolisme Moléculaire et la Physiopathologie des Stéroïdes, INSERM U 33, Medical School, University of Paris-Sud. Lab Hormones, 94270 Bicêtre, France.
- L. J. Lerner (1), Departments of Obstetrics and Gynaecology and Pharmacology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, U.S.A.
- C. Levy (413), Universidad de Buenos Aires, Instituto de Oncología "Angel H. Roffo", Avenida San Martin 5481, Buenos Aires, Argentina.
- M. E. Lippman (365), Medicine Branch, National Cancer Institute, Bethesda, Maryland 20205, U.S.A.
- S. A. McCormack (113), Department of Cell Biology, Baylor College of Medicine, Houston, Texas 77030, U.S.A.
- W. L. McGuire (339), Department of Medicine/Oncology, University of Texas Health Science Center, San Antonio, Texas 78284, U.S.A.
- A. Manni (435), Department of Medicine, Case Western Reserve University, School of Medicine, Cleveland, Ohio 44106, U.S.A.
- B. M. Markaverich (113), Department of Cell Biology, Baylor College of Medicine, Houston, Texas 77030, U.S.A.
- L. Martin (143), Department of Hormone Physiology, Imperial Cancer Research Fund, P.O. Box 123, Lincoln's Inn Fields, London WC2A 3PZ, U.K.
- N. Massol (249), Unité de Recherches sur le Métabolisme Moléculaire et la Physiopathologie des Stéroïdes, INSERM U 33, Medical School, University of Paris-Sud. Lab Hormones, 94270 Bicêtre, France.
- J. Mešter (177), Unité de Recherches sur le Métabolisme Moléculaire et la Physiopathologie des Stéroïdes, INSERM U 33, Medical School, University of Paris-Sud. Lab Hormones, 94270 Bicêtre, France.
- B. K. Milthorpe (317), Ludwig Institute for Cancer Research, University of Sydney, N.S.W. 2006, Australia.
- R. Mortel (413), Milton S. Hershey Medical Center, Hershey, Pennsylvania, U.S.A.
- L. C. Murphy (317), Ludwig Institute for Cancer Research, University of Sydney, N.S.W. 2006, Australia.
- M. Namer (413), Centre A. Lacassagne, 36, Voie Romaine, 06054 Nice, France.
- R. I. Nicholson (281), Tenovus Institute for Cancer Research, Welsh National School of Medicine, Heath Park, Cardiff CF4 4XX, U.K.
- J. S. Patterson (453), Clinical Research Department, ICI Pharmaceuticals Division, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.
- O. H. Pearson (435), Department of Medicine, Case Western Reserve University, School of Medicine, Cleveland, Ohio 44106, U.S.A.

- V. Puri (177), All India Institute of Medical Sciences, New Delhi 110016, India.
- P. Robel (413), Unité de Recherches sur le Métabolisme Moléculaire et la Physiopathologie des Stéroïdes, INSERM U 33 and CNRS ER 125, Medical School, University of Paris-Sud. Lab Hormones, 94270 Bicêtre, France.
- D. W. Robertson (95), Department of Chemistry, University of Illinois, and School of Basic Medical Sciences, University of Illinois College of Medicine, Urbana, Illinois 61801, U.S.A.
- H. Rochefort (85, 355), Unité d'Endocrinologie Cellulaire et Moléculaire (INSERM U 148), 60 rue de Navacelles, 34100 Montpellier, France.
- E. A. Rorke (303), Department of Physiology and Biophysics, University of Illinois, and School of Basic Medical Sciences, University of Illinois College of Medicine, Urbana, Illinois 61801, U.S.A.
- P. Ross Jr. (231), Department of Physiology, St. Louis University Medical Center, St. Louis, Missouri 63104, U.S.A.
- T. S. Ruh (231), Department of Physiology, St. Louis University Medical Center, St. Louis, Missouri 63104, U.S.A.
- N. Savage (339), Department of Medicine/Oncology, University of Texas Health Science Center, San Antonio, Texas 78284, U.S.A.
- D. Seeley (177), Department of Population Sciences, Harvard School of Public Health, Boston, Massachusetts 02115, U.S.A.
- R. L. Sutherland (75, 177, 195, 317, 397, 473), Ludwig Institute for Cancer Research, University of Sydney, N.S.W. 2006, Australia.
- J. S. Syne (281), Tenovus Institute for Cancer Research, Welsh National School of Medicine, Heath Park, Cardiff CF4 4XX, U.K.
- T. Tatee (95), Department of Chemistry, University of Illinois, and School of Basic Medical Sciences, University of Illinois College of Medicine, Urbana, Illinois 61801, U.S.A.
- I. W. Taylor (397), Ludwig Institute for Cancer Research, University of Sydney, N.S.W. 2006, Australia.
- T.-L. S. Tsai (303), Department of Physiology and Biophysics, University of Illinois, and School of Basic Medical Sciences, University of Illinois College of Medicine, Urbana, Illinois 61801, U.S.A.
- S. Upchurch (113), Department of Cell Biology, Baylor College of Medicine, Houston, Texas 77030, U.S.A.
- F. Vignon (355), Unité d'Endocrinologie Cellulaire et Moléculaire (INSERM U 148), 60 rue de Navacelles, 34100 Montpellier, France.
- B. Westley (355), Unité d'Endocrinologie Cellulaire et Moléculaire (INSERM U 148), 60 rue de Navacelles, 34100 Montpellier, France.
- A. M. Whybourne (75, 317, 397), Ludwig Institute for Cancer Research, University of Sydney, N.S.W. 2006, Australia.
- D. L. Williams (215), Department of Pharmacological Sciences, Health Sciences Center, State University of New York at Stony Brook, Stony Brook, New York 11794, U.S.A.
- K. I. H. Williams (165), Worcester Foundation for Experimental Biology, Shrewsbury, Massachusetts 01545, U.S.A.
- D. M. Wood (231), Department of Physiology, St. Louis University Medical Center, St. Louis, Missouri 63104, U.S.A.

# Contents

Preface	vii
List of Contributors	xix
1 The First Non-Steroidal Antioestrogen—MER 25	
Leonard J. Lerner	
I. Introduction	1
II. Antioestrogenic Properties	3
III. Oestrogenic Properties	8
IV. Antifertility Properties	10
V. Effects on Lipids	11
VI. Clinical Applications	12
VII. Clues to Future Developments	14
References	15
2 Early Work on Antioestrogens	
C. W. Emmens	
I. Introduction	17
II. Tests of Oestrogenic and Antioestrogenic Activity	18
III. Types of Antioestrogen	20
IV. Specific Compounds	22
V. Concluding Remarks	29
References	29

### 3 Structure-Activity Relationships amongst Non-Steroidal Antioestrogens

V. Craig Jordan, E. R. Clark and Karen E. Allen

I. Introduction	31
II. Structure-Activity Relationships	35
III. Application of Drug Receptor Theories	53
References	55

### 4 A Review of the Pharmacokinetics and Metabolism of "Nolvadex" (Tamoxifen)

H. K. Adam

I. Introduction	59
II. Methods of Analysis	60
III. Pharmacokinetics	62
IV. Metabolism	68
V. Discussion	71
References	73

### 5 Binding of Tamoxifen and its Metabolites 4-Hydroxytamoxifen and N-Desmethyltamoxifen to Oestrogen Receptors from Normal and Neoplastic Tissues

R. L. Sutherland and A. M. Whybourne

I. Introduction	75
II. Binding of Rat Uterine and Chick Oviduct Cytosolic Oestrogen Receptor	76
III. Binding to Chick Oviduct Nuclear Oestrogen Receptor	78
IV. Binding to Cytosolic and Nuclear Oestrogen Receptors from MCF 7 and T 47D Human Mammary Carcinoma Cells	79
V. Discussion	81
References	84

### 6 Metabolism and Binding of Non-Steroidal Antioestrogens in Mammals and Chickens

H. Rochefort, F. Capony and J. L. Borgna

I. Introduction	85
II. <i>In Vitro</i> Binding of Classical Antioestrogens to Uterine Cytosolic Oestrogen Receptor	86

III. <i>In Vivo</i> and <i>In Vitro</i> Metabolism of Tamoxifen to Hydroxylated Derivatives	89
IV. <i>In Vitro</i> Binding of Monohydroxytamoxifen to Oestrogen Receptors	92
V. Conclusions	92
References	94
<b>7 Antioestrogen Action in Uterus: Receptor Interactions and Antioestrogen Metabolism</b>	
Benita S. Katzenellenbogen, John A. Katzenellenbogen, Evan R. Ferguson, James R. Hayes, Nancy C. Lan, David W. Robertson and Tochiro Tatee	
I. Introduction: Potential Sites of Antioestrogen Action	95
II. Effects of Antioestrogens in Uterus	97
III. Receptor Interactions and Metabolism Studies with Radiolabelled Antioestrogens	103
IV. Conclusions	109
References	111
<b>8 Oestrogen Stimulation of Uterine Growth: Effects of Steroidal and Non-Steroidal Oestrogen Antagonists</b>	
Barry M. Markaverich, Susan Upchurch, Stanley R. Glasser, Shirley A. McCormack and James H. Clark	
I. Introduction	113
II. Measurement of Type I and Type II Oestrogen Binding Sites by [ <sup>3</sup> H] Oestradiol Exchange	114
III. Relationship of Type I and Type II Oestrogen Binding Sites to Uterine Growth	116
IV. Progesterone and Dexamethasone Antagonism of Type II Sites and Uterine Growth	122
V. Triphenylethylene Derivatives and Oestrogen Antagonism: Differential Cellular Response	131
VI. Conclusions	138
References	141
<b>9 Effects of Antioestrogens on Cell Proliferation in the Rodent Reproductive Tract</b>	
L. Martin	
I. Introduction	143
II. Parameters of Proliferation	144
III. Oestrogen-Induced Cell Proliferation	145



IV. Antioestrogens and Cell Proliferation in the Mouse Reproductive Tract	148
V. Antioestrogens and Cell Proliferation in the Rat Reproductive Tract	150
VI. Are Inhibitory Effects Receptor Mediated?	156
VII. Discussion	160
References	162
<b>10 Antioestrogen and Progestin Action in Diethylstilboestrol-Induced Endometrial Abnormalities in the Syrian Hamster</b>	
Wendell W. Leavitt, Rawden W. Evans, William J. Hendry III and Kenneth I. H. Williams	
I. Introduction	165
II. Tumourigenesis	166
III. Ontogeny of Diethylstilboestrol-Induced Abnormalities	167
IV. Responsiveness to Oestrogen, Progestin and Antioestrogen Action	171
V. Summary and Conclusions	175
References	175
<b>11 Mechanisms of Oestrogen Antagonism by Tamoxifen and Monohydroxytamoxifen in Chick Oviduct</b>	
J. Mešter, N. Binart, M. G. Catelli, C. Geynet, R. Hähnel, V. Puri, D. Seeley, R. L. Sutherland and E. E. Baulieu	
I. Introduction	177
II. Receptor Binding Properties	178
III. Effects on Subcellular Receptor Distribution	179
IV. Antioestrogenic Activity of Tamoxifen and Monohydroxytamoxifen	182
V. Reversibility of Oestrogen and Antioestrogenic Action	188
VI. Effects of Tamoxifen on the Progesterone-Induced Responses	192
References	193
<b>12 Synthetic Oestrogen Antagonists in Chick Oviduct: Antagonist Activity and Interactions with High-Affinity Cytoplasmic Binding Sites</b>	
R. L. Sutherland and M. S. Foo	
I. Introduction	195
II. Agonist Activity	196
III. Antagonist Activity	197



IV. Competition for Oestrogen Receptor Sites in Oviduct Cytoplasm and Nucleus	200
V. Binding Studies with Tritiated Antioestrogens	203
VI. Effect of Antioestrogens on Cytoplasmic and Nuclear Oestrogen Receptor Levels	207
VII. Discussion	209
References	213
<b>13 Antioestrogen Action in Chick Liver: Effects on Oestrogen Receptors and Oestrogen-Induced Proteins</b>	
Catherine B. Lazier, Francoise Capony and David L. Williams	
I. Introduction	215
II. The Spectrum of Oestrogenic Activities in Chick Liver	216
III. Antioestrogen Action	220
IV. Summary and Conclusions	228
References	229
<b>14 Oestrogen-Receptor and Antioestrogen-Receptor Complex Binding to Calf Uterine Chromatin</b>	
Thomas S. Ruh, David M. Wood, Patrick Ross Jr. and Jeffery L. Keene	
I. Introduction	231
II. Methodologies in Nuclear Acceptor Studies	233
III. Analysis of Oestrogen-Receptor and Antioestrogen-Receptor Complex Binding to Chromatin-Cellulose	236
IV. Conclusions	245
References	247
<b>15 Oestrogen Receptor Chromatin Interactions: Effect of Antioestrogens</b>	
M. C. Lebeau, N. Massol, and E. E. Baulieu	
I. Introduction	249
II. Oestradiol Receptor in Chromatin Prepared from Nuclease Digested Nuclei	251
III. Oestrogen Receptor in Chick Oviduct Chromatin after Oestradiol Benzoate, Tamoxifen or Monohydroxytamoxifen Administration	255
IV. Conclusions	258
References	259